- Home
- OESX vs CGTX Comparison
OESX vs CGTX Comparison
Compare OESX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OESX
- CGTX
- Stock Information
- Founded
- OESX 1996
- CGTX 2007
- Country
- OESX United States
- CGTX United States
- Employees
- OESX N/A
- CGTX N/A
- Industry
- OESX Building Products
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- OESX Consumer Discretionary
- CGTX Health Care
- Exchange
- OESX Nasdaq
- CGTX Nasdaq
- Market Cap
- OESX 26.7M
- CGTX 30.0M
- IPO Year
- OESX 2007
- CGTX 2021
- Fundamental
- Price
- OESX $0.90
- CGTX $0.58
- Analyst Decision
- OESX Strong Buy
- CGTX Strong Buy
- Analyst Count
- OESX 1
- CGTX 6
- Target Price
- OESX $3.00
- CGTX $8.30
- AVG Volume (30 Days)
- OESX 64.7K
- CGTX 809.4K
- Earning Date
- OESX 02-11-2025
- CGTX 03-25-2025
- Dividend Yield
- OESX N/A
- CGTX N/A
- EPS Growth
- OESX N/A
- CGTX N/A
- EPS
- OESX N/A
- CGTX N/A
- Revenue
- OESX $85,262,000.00
- CGTX N/A
- Revenue This Year
- OESX N/A
- CGTX N/A
- Revenue Next Year
- OESX $15.69
- CGTX N/A
- P/E Ratio
- OESX N/A
- CGTX N/A
- Revenue Growth
- OESX N/A
- CGTX N/A
- 52 Week Low
- OESX $0.68
- CGTX $0.34
- 52 Week High
- OESX $1.53
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- OESX 71.23
- CGTX 40.43
- Support Level
- OESX $0.80
- CGTX $0.57
- Resistance Level
- OESX $0.97
- CGTX $0.65
- Average True Range (ATR)
- OESX 0.04
- CGTX 0.05
- MACD
- OESX 0.01
- CGTX -0.01
- Stochastic Oscillator
- OESX 68.68
- CGTX 9.46
About OESX Orion Energy Systems Inc.
Orion Energy Systems Inc is a developer, manufacturer, and seller of lighting and energy management systems. The company segments include Orion Lighting Segment, Orion Maintenance Segment and Orion Electric Vehicle Charging Segment. It derives maximum revenue from Lighting Segment.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.